Published in J Invest Dermatol on May 06, 2010
Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis | NCT01722214
Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom. J Invest Dermatol (2011) 2.36
Immunology of psoriasis. Annu Rev Immunol (2014) 2.06
Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity (2014) 2.02
Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med (2011) 1.94
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet (2012) 1.88
Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol (2011) 1.88
Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease. PLoS One (2012) 1.70
Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol (2012) 1.69
Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol (2013) 1.64
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol (2013) 1.59
Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol (2015) 1.47
Diet and psoriasis, part I: Impact of weight loss interventions. J Am Acad Dermatol (2014) 1.45
Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis (2012) 1.31
Smoking and risk of incident psoriatic arthritis in US women. Ann Rheum Dis (2011) 1.28
Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol (2010) 1.22
Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study. J Invest Dermatol (2011) 1.14
Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res (2012) 1.11
Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech (2012) 1.09
MicroRNAs in skin and wound healing. Physiol Genomics (2010) 1.00
Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study. Arthritis Care Res (Hoboken) (2015) 1.00
Psoriasis and hypertension severity: results from a case-control study. PLoS One (2011) 0.98
IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine (2013) 0.95
The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun (2015) 0.95
Identification of a missense variant in LNPEP that confers psoriasis risk. J Invest Dermatol (2013) 0.95
Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol (2011) 0.93
Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J Rare Dis (2013) 0.91
Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities. Am J Med (2014) 0.91
IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. J Invest Dermatol (2014) 0.90
Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol (2014) 0.90
Lipin-2 reduces proinflammatory signaling induced by saturated fatty acids in macrophages. J Biol Chem (2012) 0.90
Psoriasis and Metabolic Syndrome--scientific evidence and therapeutic implications. J Med Life (2015) 0.90
Insulin resistance and skin diseases. ScientificWorldJournal (2015) 0.90
Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis. J Transl Med (2013) 0.88
Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front Med (Lausanne) (2015) 0.87
Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl (2012) 0.87
Association of cardiovascular and metabolic disease genes with psoriasis. J Invest Dermatol (2012) 0.87
Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells. Nat Commun (2015) 0.86
Psoriasis and new-onset diabetes: a Danish nationwide cohort study. Diabetes Care (2013) 0.86
Psoriasis. Cold Spring Harb Perspect Med (2014) 0.85
A marriage of two "Methusalem" drugs for the treatment of psoriasis?: Arguments for a pilot trial with metformin as add-on for methotrexate. Dermatoendocrinol (2013) 0.85
Metabolic syndrome and skin: psoriasis and beyond. Indian J Dermatol (2013) 0.83
Chronic Psoriatic Skin Inflammation Leads to Increased Monocyte Adhesion and Aggregation. J Immunol (2015) 0.82
Psoriatic disease and tuberculosis nowadays. Clin Dev Immunol (2012) 0.81
Aortic vascular inflammation in psoriasis is associated with HDL particle size and concentration: a pilot study. Am J Cardiovasc Dis (2012) 0.81
Glycyrrhizin combined with acitretin improve clinical symptom of psoriasis via reducing Th17 cell differentiation and related serum cytokine concentrations. Int J Clin Exp Med (2015) 0.81
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. Drug Des Devel Ther (2016) 0.80
Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis. F1000Res (2014) 0.80
Psoriasis and Diabetes: A Multicenter Study in 222078 Type 2 Diabetes Patients Reveals High Levels of Depression. J Diabetes Res (2015) 0.80
Novel factors in the pathogenesis of psoriasis and potential drug candidates are found with systems biology approach. PLoS One (2013) 0.80
Metabolic Syndrome and Selective Inflammatory Markers in Psoriatic Patients. J Immunol Res (2016) 0.79
Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model. J Autoimmun (2014) 0.79
The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases. J Allergy Clin Immunol (2015) 0.79
The pathophysiological role of dendritic cell subsets in psoriasis. BMB Rep (2014) 0.78
High-density lipoprotein cholesterol function improves after successful treatment of psoriasis: a step forward in the right direction. J Invest Dermatol (2014) 0.78
Kidney disease and psoriasis: novel evidences beyond old concepts. Clin Rheumatol (2015) 0.78
Nonalcoholic fatty liver disease, spleen and psoriasis: New aspects of low-grade chronic inflammation. World J Gastroenterol (2015) 0.77
Psoriasis: classical and emerging comorbidities. An Bras Dermatol (2015) 0.77
Persistent polar depletion of stratospheric ozone and emergent mechanisms of ultraviolet radiation-mediated health dysregulation. Rev Environ Health (2012) 0.76
Study on Certain Biomarkers of Inflammation in Psoriasis Through "OMICS" Platforms. Open Biochem J (2014) 0.76
Moesin and stress-induced phosphoprotein-1 are possible sero-diagnostic markers of psoriasis. PLoS One (2014) 0.76
From patients' needs to treatment outcomes in psoriasis: Results from the 'pSORRIDI' experience. J Int Med Res (2016) 0.75
Assessment of adiposity in psoriatic patients by dual energy X-ray absorptiometry compared to conventional methods. An Bras Dermatol (2016) 0.75
Sarcoidosis in patients with psoriasis: a population-based cohort study. PLoS One (2014) 0.75
Association of C-Reactive Protein (rs1205) Gene Polymorphism with Susceptibility to Psoriasis in South Indian Tamils. J Clin Diagn Res (2016) 0.75
Divergent gene activation in peripheral blood and tissues of patients with rheumatoid arthritis, psoriatic arthritis and psoriasis following infliximab therapy. PLoS One (2014) 0.75
Diabetes mellitus and the skin. An Bras Dermatol (2017) 0.75
Inositoylated platelet-activating factor (Ino-C2-PAF) modulates dynamic lymphocyte-endothelial cell interactions and alleviates psoriasis-like skin inflammation in two complementary mouse models. J Invest Dermatol (2014) 0.75
Psoriasis comorbidities: complications and benefits of immunobiological treatment. An Bras Dermatol (2017) 0.75
Psoriasis and Psoriatic Arthritis. J Clin Aesthet Dermatol (2017) 0.75
Profile of patients receiving medical care at a reference, support, and treatment center for psoriasis patients at a university hospital. An Bras Dermatol (2016) 0.75
Elucidating new drug targets in psoriasis by gene profiling: an opportunity to be seized. Ann Transl Med (2015) 0.75
Feasibility of carotid artery PET/MRI in psoriasis patients. Am J Nucl Med Mol Imaging (2016) 0.75
Psoriasis and the risk of pneumonia: a population-based study. PLoS One (2014) 0.75
Relationship between psoriasis and non-alcoholic fatty liver disease. Prz Gastroenterol (2016) 0.75
New insight into the pathogenesis of nail psoriasis and overview of treatment strategies. Drug Des Devel Ther (2017) 0.75
Clinic characteristics of psoriasis in China: a nationwide survey in over 12000 patients. Oncotarget (2017) 0.75
The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis. Curr Atheroscler Rep (2017) 0.75
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum (2010) 18.82
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med (2004) 14.53
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis (2010) 12.12
Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis (2010) 10.97
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
Major lipids, apolipoproteins, and risk of vascular disease. JAMA (2009) 10.58
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet (2009) 10.55
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90
Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet (2011) 9.07
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature (2007) 8.88
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet (2010) 8.48
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med (2010) 7.49
Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet (2012) 6.97
Pathogenesis and therapy of psoriasis. Nature (2007) 6.94
Rheumatoid arthritis association at 6q23. Nat Genet (2007) 6.71
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (2004) 6.24
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med (2012) 6.17
The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet (2011) 5.95
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet (2013) 5.34
Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med (2012) 5.12
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med (2006) 5.03
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
New therapies for treatment of rheumatoid arthritis. Lancet (2007) 4.80
Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet (2012) 4.73
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med (2003) 4.67
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet (2016) 4.49
Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology (2010) 4.43
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol (2008) 4.18
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Association of maternal weight gain in pregnancy with offspring obesity and metabolic and vascular traits in childhood. Circulation (2010) 4.12
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med (2004) 4.02
MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One (2007) 3.96
The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol (2009) 3.93
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. N Engl J Med (2016) 3.88
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet (2013) 3.83
Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med (2007) 3.68
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 3.64
OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol (2003) 3.61
IL-33 reduces the development of atherosclerosis. J Exp Med (2008) 3.59
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes (2002) 3.59
A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet (2003) 3.52
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet (2009) 3.52
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum (2006) 3.45
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics (2003) 3.39
Recommendations for musculoskeletal ultrasonography by rheumatologists: setting global standards for best practice by expert consensus. Arthritis Rheum (2005) 3.37
Serum chloride is an independent predictor of mortality in hypertensive patients. Hypertension (2013) 3.33
MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. Semin Cancer Biol (2008) 3.32
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA (2011) 3.29
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum (2006) 3.29
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis (2013) 3.25
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. Nat Genet (2008) 3.18
Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care (2002) 3.00
Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum (2002) 2.97
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis (2010) 2.91
Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol (2005) 2.83
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum (2007) 2.80
Maternal obesity is associated with dysregulation of metabolic, vascular, and inflammatory pathways. J Clin Endocrinol Metab (2002) 2.80
Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet (2007) 2.78
IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol (2009) 2.77
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med (2010) 2.74
Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol (2006) 2.70
Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med (2007) 2.70
Associations of gestational weight gain with maternal body mass index, waist circumference, and blood pressure measured 16 y after pregnancy: the Avon Longitudinal Study of Parents and Children (ALSPAC). Am J Clin Nutr (2011) 2.67
Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol (2003) 2.67
Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care (2008) 2.66
Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med (2004) 2.63
Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis (2012) 2.54
Associations of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of Parents and Children. Circulation (2012) 2.54
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A (2005) 2.47
Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. Arthritis Rheum (2004) 2.47
Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. J Clin Invest (2007) 2.46
Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol (2007) 2.45
Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum (2002) 2.44
Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum Mol Genet (2008) 2.42
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis (2014) 2.40
B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation (2009) 2.37
A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol (2003) 2.37
The relationship between metabolic risk factors and incident cardiovascular disease in Europeans, South Asians, and African Caribbeans: SABRE (Southall and Brent Revisited) -- a prospective population-based study. J Am Coll Cardiol (2013) 2.36
Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest (2004) 2.34